N-Substituted Beta-Carbolinium Compounds as P-Glycoprotein Inducers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease primarily focus on symptomatic relief and do not address the underlying issue of amyloid-β accumulation, which is driven by impaired clearance mediated by the P-glycoprotein efflux pump at the blood-brain barrier, leading to progressive neuronal damage.
Innovation Solution
Development of N-substituted beta-carbolinium compounds that act as potent P-glycoprotein inducers, increasing the expression and activity of P-glycoprotein to enhance amyloid-β clearance, thereby potentially halting disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current cholinergic-based therapies are used for Alzheimer's disease, then symptomatic relief is achieved, but the underlying amyloid-β accumulation is not addressed and disease progression continues
Solution Approach 1:
The patent introduces P-glycoprotein as an intermediary mechanism to clear amyloid-β from the brain. By developing compounds that induce P-glycoprotein expression, the invention creates a mediator system that addresses the root cause (amyloid accumulation) rather than just treating symptoms, thus resolving the contradiction between symptomatic relief and disease progression control
Solution Approach 2:
The invention changes the therapeutic parameter from cholinergic modulation to P-glycoprotein induction. By shifting the mechanism of action to enhance efflux pump activity and amyloid clearance, the patent simultaneously addresses both symptomatic treatment and underlying pathology, overcoming the limitations of current therapies
2Reliability
If P-glycoprotein activity is increased to enhance amyloid-β clearance, then disease progression is halted, but the complexity of drug development increases due to need for potent inducers
Solution Approach 1:
The patent optimizes key parameters of the beta-carbolinium compound structure, specifically the N-substitution pattern and aromatic ring substituents, to achieve potent P-glycoprotein induction at low nanomolar concentrations. This parameter optimization reduces the complexity burden by finding the most effective structural configuration
Solution Approach 2:
The invention introduces specific local substitutions on the beta-carbolinium core structure (N-substitution with aromatic groups containing halogens or trifluoromethyl groups). These localized modifications at specific positions enhance P-glycoprotein induction potency without requiring complete structural redesign, thus managing complexity while achieving high efficacy
3Reliability
If N-substituted beta-carbolinium compounds are developed as P-glycoprotein inducers, then amyloid-β clearance is enhanced, but the synthesis complexity increases
Solution Approach 1:
The patent divides the synthesis into modular segments: (1) preparation of substituted glyoxal intermediates, (2) condensation with tryptamine to form beta-carboline core, and (3) cyclization to form the carbolinium structure. This segmentation allows each step to be optimized independently, managing overall synthesis complexity while achieving high-potency compounds
Solution Approach 2:
The invention uses a universal beta-carbolinium core structure that can accommodate various aromatic substitutions (halogens, trifluoromethyl groups). This multi-functional scaffold allows a single synthetic route to produce multiple potent analogs with different substitution patterns, simplifying the overall development process while maintaining high induction potency
Data Source
AI summary
The present invention relates to the N-substituted beta-carbolinium compounds of general formula A and formulae I and II wherein, R1 and R2 groups are selected from halogens or trifluoromethyl; R3 group is selected from hydrogen or methyl; Ar is selected from aryl and heteroaryl, X is selected from halogens; and R1 and R2 groups may be attached to any position on ring E. The present invention particularly relates to synthesis and p-glycoprotein induction activity of the N-substituted beta-carbolinium compounds. In addition, the invention relates to methods of using compounds for treating or preventing Alzheimer's disease.